INNP.F Stock Overview
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
InnoCan Pharma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.20 |
| 52 Week High | CA$0.35 |
| 52 Week Low | CA$0.14 |
| Beta | 3.07 |
| 1 Month Change | -13.67% |
| 3 Month Change | 2.10% |
| 1 Year Change | 39.51% |
| 3 Year Change | -50.72% |
| 5 Year Change | n/a |
| Change since IPO | 3.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| INNP.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.1% | 2.3% | 1.6% |
| 1Y | 39.5% | 10.8% | 25.1% |
Return vs Industry: INNP.F exceeded the US Pharmaceuticals industry which returned 9.4% over the past year.
Return vs Market: INNP.F exceeded the US Market which returned 23.9% over the past year.
Price Volatility
| INNP.F volatility | |
|---|---|
| INNP.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INNP.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine INNP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Iris Bincovich | innocanpharma.com |
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management.
InnoCan Pharma Corporation Fundamentals Summary
| INNP.F fundamental statistics | |
|---|---|
| Market cap | US$55.49m |
| Earnings (TTM) | -US$4.70m |
| Revenue (TTM) | US$13.66m |
4.4x
P/S Ratio-12.7x
P/E RatioIs INNP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INNP.F income statement (TTM) | |
|---|---|
| Revenue | US$13.66m |
| Cost of Revenue | US$1.68m |
| Gross Profit | US$11.98m |
| Other Expenses | US$16.68m |
| Earnings | -US$4.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 87.71% |
| Net Profit Margin | -34.41% |
| Debt/Equity Ratio | 0% |
How did INNP.F perform over the long term?
See historical performance and comparison